公开(公告)号：US20230140384A1

公开(公告)日：2023-05-04

申请号：US17905870

申请日：2021-03-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Arvind RAJPAL ,  Aaron Paul YAMNIUK ,  Pavel STROP ,  Bryan C. BARNHART ,  Feng WANG

IPC: C07K16/28 ,  C12N15/63 ,  A61P37/04

Abstract: Provided herein are agonist antibodies that bind to human CD40 with enhanced agonist activity. Such antibodies comprise Fc regions with amino acid substitutions that enhance the agonist activity of the antibody compared with a similar IgG1 antibody. Such substitutions include sequence variants in the IgG2 hinge region and sequence variants that enhance hexamerization of the antibodies. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.

公开(公告)号：US20220281980A1

公开(公告)日：2022-09-08

申请号：US17582913

申请日：2022-01-24

Applicant: Bristol-Myers Squibb Company

Inventor： Michelle Renee KUHNE ,  Alan J. KORMAN ,  Haichun HUANG ,  Yiming YIN ,  Robert F. GRAZIANO ,  Natalie A. BEZMAN ,  Pavel STROP ,  Richard Y. HUANG ,  Guodong CHEN ,  Mohan SRINIVASAN ,  Peter Sung Keun LEE ,  Gamze Ozlem CAMDERE

IPC: C07K16/28 ,  A61P35/00 ,  C12N15/85

Abstract: The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.

公开(公告)号：US20220016260A1

公开(公告)日：2022-01-20

申请号：US17297796

申请日：2019-11-25

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pavel STROP ,  Chetana RAO-NAIK ,  Xiaodi DENG ,  Paul O. SHEPPARD ,  Patrick G. HOLDER ,  Sayumi YAMAZOE

IPC: A61K47/68 ,  C07K16/18

Abstract: An antibody has a glutamine-containing extension at the C-terminus of a light chain thereof, making it suitable for conjugation via transglutaminase-mediated transamidation.

公开(公告)号：US20220031860A1

公开(公告)日：2022-02-03

申请号：US17297830

申请日：2019-12-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pavel STROP ,  Chetana RAO-NAIK ,  Xiaodi DENG ,  Paul O. SHEPPARD ,  Sean Matthew WEST ,  Jason Michael HOGAN ,  Sayumi YAMAZOE

IPC: A61K47/68 ,  C07K16/30

Abstract: Antibodies are modified by replacing amino acids in the heavy chain CH1, CH2, or CH3 or light chain constant region with selected replacement glutamine-containing sequences to render them amenable to conjugation by the enzyme transglutaminase.

公开(公告)号：US20230416364A1

公开(公告)日：2023-12-28

申请号：US18041433

申请日：2021-08-12

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Flavio SCHWARZ ,  Xiaodi DENG ,  Pavel STROP

IPC: C07K16/28 ,  C12N15/86 ,  C07K14/715 ,  A61K38/20 ,  A61P35/00

CPC classification number: C07K16/2818 ,  C12N15/86 ,  C07K14/715 ,  A61K38/00 ,  A61P35/00 ,  C12N2740/15043 ,  C07K2319/30 ,  A61K38/2013

Abstract: The present disclosure provides constructs comprising an anti-PDI antibody, or an alternative targeting moiety, fused to CD25 or an IL-2 binding fragment of CD25. Such constructs find use in treating human diseases, such as cancer.

公开(公告)号：US20190315870A1

公开(公告)日：2019-10-17

申请号：US16362411

申请日：2019-03-22

Applicant: Bristol-Myers Squibb Company

Inventor： Michelle Renee KUHNE ,  Alan J. KORMAN ,  Haichun HUANG ,  Yiming YIN ,  Robert F. GRAZIANO ,  Natalie A. BEZMAN ,  Pavel STROP ,  Richard Y. HUANG ,  Guodong CHEN ,  Mohan SRINIVASAN ,  Peter Sung Keun LEE ,  Gamze Ozlem CAMDERE

IPC: C07K16/28 ,  C12N15/85 ,  A61P35/00

Abstract: The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.

公开(公告)号：US20220193237A1

公开(公告)日：2022-06-23

申请号：US17604711

申请日：2020-04-16

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Peter Sung Keun LEE ,  Pavel STROP ,  Arvind RAJPAL ,  Olafur S. GUDMUNDSSON ,  Pradyot NANDI

IPC: A61K39/395 ,  A61P35/00 ,  C07K16/28

Abstract: The present disclosure provides variant forms of anti-CTLA-4 antibodies, such as ipilimumab, that preferentially bind to CTLA-4 at low pH. Such antibody variants exhibit preferential activity in the tumor microenvironment, an enhanced ratio of anti-tumor response to side-effects, and an enhanced therapeutic index.